PERK inhibitors, GSK2606414 and its derivative GSK2656157 optimized for clinical investigation have been tested in different types of tumors such as pancreatic cancer and multiple myeloma [56, 57]. The gene discussed is EIF2AK3; the disease is familial pancreatic carcinoma.